Last update 23 Sep 2026

VBC106

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
VBC-106
Target
Top I
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication
Advanced Malignant Solid NeoplasmEndometrial CarcinomaHER2 Positive Gastrointestinal Neoplasms+ [4]
Inactive Indication-
Originator Organization
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,Ltd
Active Organization
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,LtdVelaVigo Bio Inc
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H22FN3O4
InChIKeyZVYVPGLRVWUPMP-FYSMJZIKSA-N
CAS Registry171335-80-1
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with VBC106
NCT07686068
/ Not yet recruitingPhase 1/2
Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors
100 Clinical Results associated with VBC106
Login to view more data
100 Translational Medicine associated with VBC106
Login to view more data
100 Patents (Medical) associated with VBC106
Login to view more data
100 Deals associated with VBC106
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
United States
VelaVigo Bio Inc
18 Aug 2026
Advanced Malignant Solid NeoplasmPhase 2
Australia
VelaVigo Bio Inc
18 Aug 2026
Endometrial CarcinomaIND Approval
China
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,Ltd
02 Sep 2026
HER2 Positive Gastrointestinal NeoplasmsIND Approval
China
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,Ltd
02 Sep 2026
Mesothelioma, MalignantIND Approval
China
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,Ltd
02 Sep 2026
Ovarian CancerIND Approval
China
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,Ltd
02 Sep 2026
Triple Negative Breast CancerIND Approval
China
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,Ltd
02 Sep 2026
Non-Small Cell Lung CancerIND Approval
China
Velavigo Shanghai Pharmaceutical Co.,LtdVelavigo Shanghai Pharmaceutical Co.,Ltd
02 Sep 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free